60 related articles for article (PubMed ID: 19538231)
21. The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.
Seber S; Ucak S; Basat O; Altuntas Y
Diabetes Res Clin Pract; 2006 Jan; 71(1):52-8. PubMed ID: 16009445
[TBL] [Abstract][Full Text] [Related]
22. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.
Berhanu P; Kipnes MS; Khan MA; Perez AT; Kupfer SF; Spanheimer RC; Demissie S; Fleck PR
Diab Vasc Dis Res; 2006 May; 3(1):39-44. PubMed ID: 16784180
[TBL] [Abstract][Full Text] [Related]
23. [Atherogenic dyslipidaemia in type 2 diabetes].
Zozulińska D
Kardiol Pol; 2006 Oct; 64(10 Suppl 6):S567-71. PubMed ID: 20527378
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia.
Yin WH; Jen HL; Chen JW; Lin SJ; Young MS
Diabetes Metab; 2006 Jun; 32(3):229-35. PubMed ID: 16799399
[TBL] [Abstract][Full Text] [Related]
25. Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients.
Wang J; Bao YQ; Hu C; Zhang R; Wang CR; Lu JX; Jia WP; Xiang KS
Acta Pharmacol Sin; 2008 Feb; 29(2):252-8. PubMed ID: 18215356
[TBL] [Abstract][Full Text] [Related]
26. Meta-analysis of Atherogenic Index of Plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus.
Zhu XW; Deng FY; Lei SF
Prim Care Diabetes; 2015 Feb; 9(1):60-7. PubMed ID: 24810146
[TBL] [Abstract][Full Text] [Related]
27. A pan-PPAR agonist E17241 ameliorates hyperglycemia and diabetic dyslipidemia in KKAy mice via up-regulating ABCA1 in islet, liver, and white adipose tissue.
Sheng R; Li Y; Wu Y; Liu C; Wang W; Han X; Li Y; Lei L; Jiang X; Zhang Y; Zhang Y; Li S; Hong B; Liu C; Xu Y; Si S
Biomed Pharmacother; 2024 Mar; 172():116220. PubMed ID: 38308968
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of hepatic LRP1 by rosiglitazone: a possible novel mechanism of the beneficial effect of thiazolidinediones on atherogenic dyslipidemia.
Moon JH; Kim HJ; Kim HM; Yang AH; Lee BW; Kang ES; Lee HC; Cha BS
J Mol Endocrinol; 2012 Dec; 49(3):165-74. PubMed ID: 22889684
[TBL] [Abstract][Full Text] [Related]
29. [The change of atherogenic index of plasma (AIP) level in type 2 diabetic pedigrees and the response of AIP to Acarbose or Glimepiride in therapy of type 2 diabetes mellitus].
Yang B; Tian H; Ren Y; Tong N; Yu H; Han L; Ran X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Jun; 22(3):560-4. PubMed ID: 16013260
[TBL] [Abstract][Full Text] [Related]
30. Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist.
Badeau RM; Honka MJ; Lautamäki R; Stewart M; Kangas AJ; Soininen P; Ala-Korpela M; Nuutila P
Ann Med; 2014 Feb; 46(1):18-23. PubMed ID: 24266715
[TBL] [Abstract][Full Text] [Related]
31. The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes.
Kang ES; Cha BS; Kim HJ; Kim HJ; Kim SH; Hur KY; Lee HJ; Shim WS; Ahn CW; Lee HC
Diabetes Care; 2006 Jun; 29(6):1320-4. PubMed ID: 16732015
[TBL] [Abstract][Full Text] [Related]
32. LPIN1 genetic variation is associated with rosiglitazone response in type 2 diabetic patients.
Kang ES; Park SE; Han SJ; Kim SH; Nam CM; Ahn CW; Cha BS; Kim KS; Lee HC
Mol Genet Metab; 2008; 95(1-2):96-100. PubMed ID: 18693052
[TBL] [Abstract][Full Text] [Related]
33. The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes.
Stage TB; Christensen MM; Feddersen S; Beck-Nielsen H; Brøsen K
Pharmacogenet Genomics; 2013 Apr; 23(4):219-27. PubMed ID: 23426382
[TBL] [Abstract][Full Text] [Related]
34.
Ajabnoor GMA; Bahijri SM; Alrashidi W; Enani SM; Alamoudi AA; Al Sheikh L; Eldakhakhny B
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553543
[TBL] [Abstract][Full Text] [Related]
35. The longitudinal effect of the atherogenic index of plasma on type 2 diabetes in middle-aged and older Chinese.
Yi Q; Ren Z; Bai G; Zhu S; Li S; Li C; Wu H; Zhu Y; Song P
Acta Diabetol; 2022 Feb; 59(2):269-279. PubMed ID: 34648090
[TBL] [Abstract][Full Text] [Related]
36. The marketing of unproven drugs for diabetes and dyslipidaemia in India.
Luthra A; Misra A
Lancet Diabetes Endocrinol; 2015 Oct; 3(10):758-60. PubMed ID: 26386988
[No Abstract] [Full Text] [Related]
37. Emerging Strategies for the Management of Atherogenic Dyslipidaemia.
Agarwala A; Shapiro MD
Eur Cardiol; 2020 Feb; 15():1-3. PubMed ID: 32180837
[No Abstract] [Full Text] [Related]
38. Genetic Variants and Their Associations to Type 2 Diabetes Mellitus Complications in the United Arab Emirates.
ElHajj Chehadeh S; Sayed NS; Abdelsamad HS; Almahmeed W; Khandoker AH; Jelinek HF; Alsafar HS
Front Endocrinol (Lausanne); 2021; 12():751885. PubMed ID: 35069435
[TBL] [Abstract][Full Text] [Related]
39. Association between ABC family variants rs1800977, rs4149313, and rs1128503 and susceptibility to type 2 diabetes in a Chinese Han population.
Yan R; Luo J; He X; Li S
J Int Med Res; 2020 Aug; 48(8):300060520941347. PubMed ID: 32762489
[TBL] [Abstract][Full Text] [Related]
40. A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.
Han E; Park HS; Kwon O; Choe EY; Wang HJ; Lee YH; Lee SH; Kim CH; Kim LK; Kwak SH; Park KS; Kim CS; Kang ES
Medicine (Baltimore); 2016 Nov; 95(44):e5155. PubMed ID: 27858848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
